QTERN (saxagliptin/dapagliflozin)

QTERN™ is a fixed dose combination of saxagliptin and dapagliflozin and is indicated in adults aged 18 years and older with type 2 diabetes mellitus1

References

  1. QTERNTM (saxagliptin and dapagliflozin) Summary of Product Characteristics, http://www.medicines.org.uk/emc/medicine/32750 (Last accessed November 2017).
  2. Bailey CJ, et al. Lancet 2010; 37: 2223–2233.
  3. Bailey CJ, et al. BMC Med 2013; 11: 43.
  4. Del Prato S, et al. Diabetes Obes Metab 2015; 17: 581–590.
  5. Matthaei S, et al. Diabetes Care 2015; 38: 2018–2024.
  6. FORXIGA® Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/27188 (Last accessed November 2017). 
  7. Lokhandwala T, et al. J Med Econ 2016; 19: 203–212.
  8. ONGLYZA® Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/22315 (Last accessed November 2017).
  9. Matthaei S, et al. Diabetes Obes Metab 2016; 18: 1128–1133.
  10. Mathieu C, et al. Diabetes Care 2015; 38: 2009–2017.
  11. FORXIGA® MIMS price. http://www.mims.co.uk/drugs/diabetes/oral-and-parenteral-hypoglycaemics/forxiga (Last accessed November 2017).
  12. ONGLYZA® MIMS price. http://www.mims.co.uk/drugs/diabetes/oral-and-parenteral-hypoglycaemics/onglyza (Last accessed November 2017).
  13. QTERNTM MIMS price. http://www.mims.co.uk/drugs/diabetes/oral-and-parenteral-hypoglycaemics/qtern (Last accessed November 2017).

 

GB-9783

Date of preparation: November 2017.